Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study.
Darren R HargraveEric BouffetUri TaboriAlberto BroniscerKenneth J CohenJordan R HansfordBirgit GeoergerPooja HingoraniIra J DunkelMark W RussoLillian TsengKohinoor DasguptaEduard GasalJames A WhitlockMark W KieranPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Dabrafenib demonstrated meaningful clinical activity and acceptable tolerability in patients with BRAF V600-mutant pLGG.